Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 0900 • ACR Convergence 2021
The Phenomenon of Fused Sacroiliac Joints but Absent Syndesmophytes in Long Standing Ankylosing Spondylitis Patients: Data from a Prospectively Followed Cohort
Lauren Ridley¹, Mark Hwang², John Reveille³, Lianne Gensler⁴, Mariko Ishimori⁵, Matthew Brown⁶, Mohammad Rahbar⁷, Amirali Tahanan⁸, Michael Ward⁹, Michael Weisman¹⁰ and Thomas Learch¹¹, ¹McGovern Medical School, Katy, TX, ²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ³Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Cedars-Sinai Health System, Los Angeles, CA, ⁶King's College London, London, United Kingdom, ⁷Division of Clinical and Translational Sciences, Department of Internal Medicine, The University of Texas Health Science Center at Houston, Houston, TX, ⁸McGovern Medical School, Houston, TX, ⁹Intramural Research Program, National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, Maryland, United States, Rockville, MD, ¹⁰Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹¹Cedars-Sinai, Los Angeles, CA
Background/Purpose: Ankylosing Spondylitis describes disorders of inflammation and damage to the spine and sacroiliac (SI) joints. Clinicians have observed, on occasion, AS subjects with fused…
Abstract Number: 0923 • ACR Convergence 2021
Minimal Impact of the COVID-19 Pandemic on Patient-Reported Disease Activity and Health-Related Quality of Life in Patients with Ankylosing Spondylitis Receiving Bimekizumab: Post Hoc Analyses from a Phase 2b Study
Philip Robinson¹, Pedro Machado², Nigil Haroon³, Lianne Gensler⁴, John Reveille⁵, Vanessa Taieb⁶, Thomas Vaux⁶, Carmen Fleurinck⁷, Marga Oortgiesen⁸, Natasha de Peyrecave⁷ and Atul Deodhar⁹, ¹University of Queensland School of Clinical Medicine, Brisbane, Queensland, Australia, Herston, Australia, ²Centre for Rheumatology & Department of Neuromuscular Diseases, University College London, London, United Kingdom, ³Division of Rheumatology, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada, ⁴Department of Rheumatology, University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, The University of Texas Health Science Center at Houston, Houston, TX, ⁶UCB Pharma, Slough, United Kingdom, ⁷UCB Pharma, Brussels, Belgium, ⁸UCB Pharma, Raleigh, NC, ⁹Oregon Health & Science University, Portland, OR
Background/Purpose: Bimekizumab (BKZ), a monoclonal IgG1 antibody that inhibits both interleukin (IL)-17A and IL-17F, has been demonstrated to be efficacious and well tolerated in patients…
Abstract Number: 1322 • ACR Convergence 2021
Body Mass Index (BMI) Underestimates Obesity in Females with Axial Spondyloarthropathy
Sinead Maguire¹, Wilson Fiona², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Worldwide prevalence of obesity has been steadily increasing, despite public health campaigns to raise awareness. In axial spondyloarthropathy (axSpA) obesity has been shown to…
Abstract Number: 0158 • ACR Convergence 2021
The Influence of Age on the Prevalence of Inflammatory and Post-inflammatory MRI Lesions in the Sacroiliac Joints of Patients with and Without Axial Spondyloarthritis
Xenofon Baraliakos, Styliani Tsiami, Anna Kühn, Martin Fruth and Jürgen Braun, Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany
Background/Purpose: Axial spondyloarthritis (axSpA) is clinically characterized by chronic inflammatory back pain and by inflammatory and structural changes in the sacroiliac joint (SIJ) as assessed…
Abstract Number: 0385 • ACR Convergence 2021
The Diagnostic Utility of Serum interleukin-22 in Patients with Suspected Axial Spondyloarthritis
Michal Sagiv¹, Abid Awisat², Aniela Shouval², Regina Peri³, Mohammad Adawi⁴, Firas Sabbah⁴, Itzhak Rosner², Aharon Kessel³ and Gleb Slobodin², ¹Faculty of Medicine, Bar Ilan University, Tel Aviv, Israel, ²Rheumatology Unit, Bnai Zion Medical Center, Haifa, Israel, ³Clinical Immunology and Allergy Division, Bnai Zion Medical Center, Haifa, Israel, ⁴Puria Medical Center, Tiberias, Israel
Background/Purpose: There is an unmet need for a reliable biomarker for the diagnosis and differentiation of AxSpA from its multiple mimickers. Serum levels of IL-22,…
Abstract Number: 0901 • ACR Convergence 2021
Low Dose Dual Energy CT Scan for the Detection of Bone Marrow Edema and Erosions in Axial Spondyloarthritis
Jonathan Chan¹, Savvas Nicolaou¹, Yet Yen Yan², Mahomed Osman³, Hugue Ouellette¹ and Sabeena Jalal⁴, ¹University of British Columbia, Vancouver, BC, Canada, ²Changi General Hospital, Singapore, ³Queensland X-ray, Brisbane, Australia, ⁴Harvard School of Public Health, Boston, USA, Boston, MA
Background/Purpose: Bone marrow edema (BME) and erosions of the sacroiliac (SI) joints are key imaging features in the diagnosis of axial spondyloarthritis (axSpA). MRI with…
Abstract Number: 0927 • ACR Convergence 2021
Whole Blood Transcriptional Changes Following Treatment with Filgotinib in Patients with Ankylosing Spondylitis
Denis Poddubnyy¹, Yihua Liu², William Barchuk³, Robin Besuyen⁴, René Galien⁵, Yuan Tian², Vlad Malkov² and Angie Hertz², ¹Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos BV, Leiden, Netherlands, ⁵Galapagos NV, Romainvulle, France
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…
Abstract Number: 1361 • ACR Convergence 2021
Impact of Intermediate Treatment Interruption on Secukinumab Efficacy in Patients with Active Psoriatic Arthritis and Ankylosing Spondylitis: Interim Analysis Results from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Nicola Gullick³, Gkikas Katsifis⁴, Anna Kandyli⁵, Jan Brandt-Jrgens⁶, Philippe Goupille⁷, Nicola Maiden⁸, Karl Gaffney⁹, Maher Aassi¹⁰, Barbara Schulz¹⁰, Effie Pournara¹⁰ and Piotr Jagiello¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²National Kapodistrian University of Athens Medical School, Athens, Greece, Athens, Greece, ³University Hospitals Coventry & Warwickshire, Coventry, United Kingdom, ⁴Rheumatology Clinic Naval Hospital of Athens, Athens, Greece, ⁵Rheumatology Outpatient Clinic, Iaso General Hospital, Athens, Greece, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷University hospital of Tours, Rheumatology department, Tours, France, ⁸Craigavon Area Hospital, Southern Health & Social Care Trust, Portadown, Craigavon BT63 5QQ, Craigavon, United Kingdom, ⁹Norfolk and Norwich University Hospital NHS Trust, Norwich, United Kingdom, ¹⁰Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab (SEC) has demonstrated long-lasting efficacy and a favorable safety profile in patients (pts) with psoriatic arthritis (PsA) and ankylosing spondylitis (AS) across Phase…
Abstract Number: 0159 • ACR Convergence 2021
Structural Damage in Axial Spondyloarthritis: Is There a Preferred Way to Assess Progression over Time?
Xenofon Baraliakos¹, Valeria Rios Rodriguez², Murat Torgutalp², Anil Dilbaryan², Hildrun Haibel³, Maryna Verba⁴, Joachim Sieper³, Jürgen Braun¹, Martin Rudwaleit⁵ and Denis Poddubnyy⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany, ⁴Charité – Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin Department of Gastroenterology, Infectiology and Rheumatology (including Nutrition Medicine), Berlin, Germany, ⁵University of Bielefeld, Klinikum Bielefeld, Bielefeld, Germany, ⁶Department of Rheumatology, Charité – Universitätsmedizin, Berlin, Germany
Background/Purpose: The aim of this study is to investigate the performance of the modified Stokes Ankylosing Spondylitis Scoring System (mSASSS) in assessing spinal radiographic damage…
Abstract Number: 0386 • ACR Convergence 2021
Delay to Diagnosis in Axial Spondyloarthritis: The Gap Is Closing, but Persistent Association with Severe Disease
Maria McWalter¹, Conall MacGearailt¹, Sinead Maguire², Finbar (Barry) O'Shea² and Gillian Fitzgerald³, ¹Galway University Hospitals, Galway, Ireland, ²St James's Hospital, Dublin, Ireland, ³Galway University Hospital, Galway, Ireland
Background/Purpose: Diagnostic delay in axial spondyloarthritis (axSpA) presents a challenge in the management of the condition, despite increased awareness. Reducing the gap between symptom onset…
Abstract Number: 0902 • ACR Convergence 2021
Does Imaging of the Sacroiliac Joint and Spine Differ in Patients Presenting with Undiagnosed Back Pain and Psoriasis, Acute Anterior Uveitis, and Colitis: An Inception Cohort Study
Walter Maksymowych¹, Ulrich Weber², Jonathan Chan³, Raj Carmona⁴, James Yeung⁵, Sibel Zehra Aydin⁶, Jodie Reis⁷, Liam Martin⁸, Ariel Masetto⁹, Olga Ziouzina⁸, Dianne Mosher⁸, Stephanie Keeling¹⁰, Sherry Rohekar¹¹, Rana Dadashova¹², Joel Paschke¹², Amanda Carapellucci¹² and Robert Lambert¹³, ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Practice Buchsbaum Schaffhausen, Schaffhausen, Switzerland, ³University of British Columbia, Vancouver, BC, Canada, ⁴St. Joseph's Healthcare Hamilton, Mississauga, ON, Canada, ⁵James Yeung Rheumatology, Richmond, BC, Canada, ⁶University of Ottawa , Faculty of Medicine, Rheumatology, Ottawa, ON, Canada, ⁷Polmed Research Inc, Saskatoon, Canada, ⁸University of Calgary, Calgary, AB, Canada, ⁹Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Division of Rheumatology, University of Alberta, Edmonton, AB, Canada, ¹¹University of Western Ontario - London, London, ON, Canada, ¹²CARE Arthritis, Edmonton, AB, Canada, ¹³University of Alberta, Edmonton, AB, Canada
Background/Purpose: Diagnosis and classification of axial spondyloarthritis (axSpA) relies considerably on imaging evidence of sacroiliitis which has led to the development of classification criteria which…
Abstract Number: 0928 • ACR Convergence 2021
Filgotinib Treatment Results in Reduction of Inflammatory and Matrix Remodeling Biomarkers Associated with Disease in Patients with Ankylosing Spondylitis
Walter Maksymowych¹, Yuan Tian², Jingting Xu², William Barchuk³, René Galien⁴, Robin Besuyen⁵, Yihua Liu², Vlad Malkov² and Angie Hertz², ¹Department of Medicine, University of Alberta, Alberta, Canada, Edmonton, AB, Canada, ²Gilead Sciences, Foster City, CA, ³Gilead Sciences, Inc., Foster City, CA, ⁴Galapagos NV, Romainvulle, France, ⁵Galapagos BV, Leiden, Netherlands
Background/Purpose: Ankylosing spondylitis (AS) – also referred to as radiographic axial spondyloarthritis – is a chronic inflammatory disease that affects the sacroiliac joints and spine.…
Abstract Number: 1691 • ACR Convergence 2021
Long-Term Safety Profile of Upadacitinib in Patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Gerd Burmester¹, Stanley Cohen², Kevin Winthrop³, Peter Nash⁴, Andrea Rubbert-Roth⁵, Atul Deodhar³, Ori Elkayam⁶, Eduardo Mysler⁷, Yoshiya Tanaka⁸, Jianzhong Liu⁹, Ana Paula Lacerda⁹, Bosny Pierre-Louis⁹, Tim Shaw¹⁰ and Philip Mease¹¹, ¹Charité University Medicine Berlin, Berlin, Germany, ²Metroplex Clinical Research Center, Dallas, TX, ³Oregon Health & Science University, Portland, OR, ⁴Griffith University, Brisbane, Australia, ⁵Kantonspital St Gallen, St.Gallen, Switzerland, ⁶Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ⁷Organización Medica de Investigación, Rheumatology, Buenos Aires, Argentina, ⁸University of Occupational and Environmental Health, Kitakyushu, Japan, ⁹AbbVie Inc., North Chicago, IL, ¹⁰AbbVie Inc., North Chicago, ¹¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA
Background/Purpose: The efficacy and safety of the oral Janus kinase inhibitor, upadacitinib (UPA), has been evaluated for several rheumatic diseases. The objective of this analysis…
Abstract Number: 0357 • ACR Convergence 2021
Identifying Predictors of Unemployment in Axial Spondyloarthropathy: Data from the Ankylosing Spondylitis Registry of Ireland
Sinead Maguire¹, Wilson Fiona², Phil Gallagher³ and Finbar (Barry) O'Shea¹, ¹St James's Hospital, Dublin, Ireland, ²Discipline of Physiotherapy, Trinity College Dublin, Dublin, Ireland, ³St Vincent's Hospital, Dublin, Ireland
Background/Purpose: Axial spondyloarthropathy (axSpA) is an inflammatory arthritis of the axial skeleton. Persistent disease activity can result in significant disability and affect ability to maintain…
Abstract Number: 0489 • ACR Convergence 2021
CC-99677: A Novel, Oral, Selective MK2 Inhibitor with Sustainable Multi-Cytokine Inhibition for the Treatment of Ankylosing Spondylitis and Other Inflammatory Diseases
Kofi Mensah¹, Rajula Gaur¹, Jamie Connarn¹, Michael Thomas¹, Liangang Liu¹, Stuart Mair², Francisco Ramírez-Valle¹ and Maria Palmisano¹, ¹Bristol Myers Squibb, Princeton, NJ, ²Quotient Sciences, Nottingham, United Kingdom
Background/Purpose: Inhibitors of p38 are associated with tachyphylaxis in patients with RA and other inflammatory diseases, where early reduction in ex vivo production of cytokines,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].